Oxford Biomedica (OXB) Competitors

Oxford Nanopore Technologies (LON:ONT) and Oxford Biomedica (LON:OXB) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, profitability, risk, dividends, valuation, media sentiment, earnings and community ranking.

Which has more volatility and risk, ONT or OXB?

Oxford Nanopore Technologies has a beta of 0.8, suggesting that its share price is 20% less volatile than the S&P 500. Comparatively, Oxford Biomedica has a beta of 1.09, suggesting that its share price is 9% more volatile than the S&P 500.

Which has better valuation and earnings, ONT or OXB?

Oxford Biomedica has lower revenue, but higher earnings than Oxford Nanopore Technologies. Oxford Nanopore Technologies is trading at a lower price-to-earnings ratio than Oxford Biomedica, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Oxford Nanopore Technologies	£167.75M	7.60	-£159.06M	-£0.20	-677.50
Oxford Biomedica	£97.28M	4.39	-£142.02M	-£1.44	-281.25

Do insiders & institutionals have more ownership in ONT or OXB?

38.4% of Oxford Nanopore Technologies shares are owned by institutional investors. Comparatively, 64.1% of Oxford Biomedica shares are owned by institutional investors. 32.6% of Oxford Nanopore Technologies shares are owned by company insiders. Comparatively, 21.2% of Oxford Biomedica shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Is ONT or OXB more profitable?

Oxford Nanopore Technologies has a net margin of -94.82% compared to Oxford Biomedica's net margin of -145.98%. Oxford Nanopore Technologies' return on equity of -26.08% beat Oxford Biomedica's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Oxford Nanopore Technologies	-94.82%	-26.08%	-14.42%
Oxford Biomedica	-145.98%	-124.66%	-12.67%

Do analysts rate ONT or OXB?

Oxford Nanopore Technologies currently has a consensus target price of GBX 235.50, suggesting a potential upside of 73.80%. Oxford Biomedica has a consensus target price of GBX 433.33, suggesting a potential upside of 7.00%. Given Oxford Nanopore Technologies' stronger consensus rating and higher probable upside, equities research analysts plainly believe Oxford Nanopore Technologies is more favorable than Oxford Biomedica.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Oxford Nanopore Technologies	0 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	3.00
Oxford Biomedica	0 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.33

Does the media favor ONT or OXB?

In the previous week, Oxford Biomedica had 3 more articles in the media than Oxford Nanopore Technologies. MarketBeat recorded 3 mentions for Oxford Biomedica and 0 mentions for Oxford Nanopore Technologies. Oxford Nanopore Technologies' average media sentiment score of 0.00 equaled Oxford Biomedica'saverage media sentiment score.

Company	Overall Sentiment
Oxford Nanopore Technologies	Neutral
Oxford Biomedica	Neutral

Does the MarketBeat Community believe in ONT or OXB?

Oxford Biomedica received 327 more outperform votes than Oxford Nanopore Technologies when rated by MarketBeat users. However, 100.00% of users gave Oxford Nanopore Technologies an outperform vote while only 66.73% of users gave Oxford Biomedica an outperform vote.

Company	Underperform	Outperform
Oxford Nanopore Technologies	Outperform Votes 32 100.00%	Underperform Votes No Votes
Oxford Biomedica	Outperform Votes 359 66.73%	Underperform Votes 179 33.27%

Summary

Oxford Nanopore Technologies beats Oxford Biomedica on 10 of the 17 factors compared between the two stocks.